TransMedics Group, Inc. (NASDAQ:TMDX) reported a significant transaction by Chief Commercial Officer Khayal Tamer I, involving both the sale of common stock and the acquisition of stock options, according to a recent filing. On May 6, 2024, Tamer sold 5,839 shares of TransMedics at a weighted average price of $130.07, totaling approximately $759,478. The transactions ranged from $130.00 to $130.23 per share, with the company prepared to provide full details of the sales upon request.
On the same day, Tamer also acquired an equivalent number of stock options at $66.10 each, amounting to a total transaction value of $385,957. These options vest monthly and are set to be fully vested by February 20, 2027. The transactions were made under a Rule 10b5-1 trading plan, which was established on September 6, 2023.
Following the sale, Tamer's direct holdings in TransMedics common stock decreased, but the acquisition of options signals ongoing investment in the company's future. Additionally, Tamer has indirect ownership through the Tamer Ibrahim Ahmed Khayal Trust, holding 11,051 shares of common stock.
Investors and stakeholders in TransMedics may find this information useful as they assess the company's insider transactions and their potential implications.
InvestingPro Insights
As TransMedics Group, Inc. (NASDAQ:TMDX) navigates through its corporate activities, including significant insider transactions, real-time data and analytics from InvestingPro can offer a deeper understanding of the company's financial health and stock performance. Here are some key insights:
InvestingPro Data reveals that TransMedics has a market capitalization of approximately $4.19 billion. The company has experienced substantial revenue growth over the last twelve months as of Q1 2024, with an increase of 149.23%, indicating a strong upward trajectory in its financial performance. Despite not yet being profitable, with a negative return on assets of -2.02%, the company's stock has shown considerable momentum, with a one-month price total return of 41.53% and a six-month price total return of 107.94% as of the most recent data point.
Two InvestingPro Tips highlight the company's stock market behavior. Firstly, the stock is currently trading near its 52-week high, at 95.71% of the peak, suggesting investor confidence and a potentially bullish outlook. Secondly, the Relative Strength Index (RSI) indicates that TransMedics' stock is in overbought territory, which could imply a need for caution among investors considering entering or exiting positions.
For investors looking to delve deeper into TransMedics' financials and stock performance, additional InvestingPro Tips are available at https://www.investing.com/pro/TMDX. With the provided coupon code PRONEWS24, readers can enjoy an extra 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to an extensive range of analytical tools and insights that could further inform their investment decisions. There are 19 more InvestingPro Tips available for TransMedics, offering a comprehensive analysis of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.